Ethel Weld, MD

Protocol chair, IMPAACT 2005
Protocol vice-chair, IMPAACT 2022
Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
Member, Pharmacology Core, HPTN Laboratory Core
Member, TB in Pregnancy Working Group
Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Johns Hopkins University Baltimore-India Clinical Trials Unit